BioSpace News Archive

Pharm Country

Insmed Announces Proposed $500 Million Public Offering of Common Stock

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering.

May 28, 2024
·
11 min read
BioMidwest

Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Docetaxel Injection, USP Due to Potential Presence of Particulate Matter

Sagent Pharmaceuticals announced the voluntary nationwide recall of two lots of Docetaxel Injection, USP.

May 28, 2024
·
2 min read
Drug Development

AstraZeneca, Daiichi Sankyo ADC Misses Endpoint in Phase III NSCLC Study

AstraZeneca and Daiichi Sankyo’s investigational antibody-drug conjugate Dato-DXd failed to significantly improve overall survival in non-small cell lung cancer patients versus docetaxel.

May 28, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Novartis Eyes Rare Kidney Disease Approvals on Heels of Two Phase III Wins

With back-to-back victories in IgA nephropathy and C3 glomerulopathy, Novartis on Saturday said it is planning to make regulatory submissions for the rare kidney diseases this year.

May 28, 2024
·
2 min read
·
Tristan Manalac
Policy

Novo Nordisk’s Once-Weekly Insulin Loses FDA Adcomm Vote for Type 1 Diabetes

Flagging a risk of hypoglycemia, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee on Friday did not recommend the approval of Novo Nordisk’s once-weekly insulin icodec for type 1 diabetes.

May 28, 2024
·
2 min read
·
Tristan Manalac
Drug Development

NS Pharma’s DMD Candidate Viltespo Fails Confirmatory Phase III Trial

NS Pharma, a subsidiary of Nippon Shinyaku, announced Monday that its Duchenne muscular dystrophy candidate Viltepso failed a late-stage confirmatory trial, showing no significant motor function improvements over placebo.

May 28, 2024
·
2 min read
·
Tristan Manalac
Deals

Asahi Kasei Offers $1.1B for Swedish Pharma Calliditas Therapeutics

The potential purchase by the Japanese conglomerate could secure access to Calliditas’ IgA nephropathy therapy Tarpeyo, which won the FDA’s full approval in December 2023.

May 28, 2024
·
2 min read
·
Tyler Patchen
Drug Development

J&J Inks $1.25B Deal to Buy Rights to Atopic Dermatitis Candidate from Numab

Johnson & Johnson’s deal for Numab Therapeutics’ bispecific antibody NM26, slated to enter Phase II studies, comes on the heels of J&J’s $850 million Proteologix bispecific antibody acquisition.

May 28, 2024
·
2 min read
·
Tyler Patchen
Business

AstraZeneca’s Ambitious Target, Pharma Layoffs Continue and ASCO

AstraZeneca targets $80 billion in revenue by 2030, layoffs at Bayer, BMS and Pfizer continue to generate attention across the biopharma industry, Takeda takes a deep dive into the molecular glue space and conference season is in full swing.

May 28, 2024
·
1 min read
·
Greg Slabodkin, Heather McKenzie, Tyler Patchen
Business

How Realistic is AstraZeneca’s $80B Revenue Target by 2030?

AstraZeneca last week set another ambitious goal, this time with plans to nearly double its total revenue by the end of the decade. However, it’s easier said than done, according to analysts.

May 28, 2024
·
4 min read
·
Tyler Patchen